| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3850897 | American Journal of Kidney Diseases | 2010 | 8 Pages |
Abstract
Recent events affecting ESA use in dialysis patients have had the desired effect of increasing the proportion of Hb measurements within the US Food and Drug Administration recommended target range of 10-12 g/dL and decreasing the proportion of Hb measurements >12 g/dL. However, the proportion of Hb measurements <10 g/dL also has increased. Benefits of a decrease in Hb measurements in the >12 g/dL range need to be considered, together with risks of having low Hb levels.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
David M. MD, Irfan PhD, Mahesh MD, MPH, Tracy J. PhD,